<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01//EN"
                      "http://www.w3.org/TR/html4/strict.dtd">
<html lang="en">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=US-ASCII">
<meta name="generator" content="hypermail 2.1.5, see http://www.hypermail.org/">
<title>Extropians: RE: Performance enhancement with selegiline</title>
<meta name="Author" content="gts (gts_2000@yahoo.com)">
<meta name="Subject" content="RE: Performance enhancement with selegiline">
<meta name="Date" content="2003-02-10">
<style type="text/css">
body {color: black; background: #ffffff}
h1.center {text-align: center}
div.center {text-align: center}
</style>
</head>
<body>
<h1>RE: Performance enhancement with selegiline</h1>
<!-- received="Mon Feb 10 01:28:33 2003" -->
<!-- isoreceived="20030210082833" -->
<!-- sent="Mon, 10 Feb 2003 03:29:48 -0500" -->
<!-- isosent="20030210082948" -->
<!-- name="gts" -->
<!-- email="gts_2000@yahoo.com" -->
<!-- subject="RE: Performance enhancement with selegiline" -->
<!-- id="015f01c2d0de$93d8a0c0$5b2093d0@MyPC" -->
<!-- charset="US-ASCII" -->
<!-- inreplyto="013e01c2d07e$9fa51c90$5b2093d0@MyPC" -->
<!-- expires="-1" -->
<p>
<strong>From:</strong> gts (<a href="mailto:gts_2000@yahoo.com?Subject=RE:%20Performance%20enhancement%20with%20selegiline"><em>gts_2000@yahoo.com</em></a>)<br>
<strong>Date:</strong> Mon Feb 10 2003 - 01:29:48 MST
</p>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2431.html">gts: "RE: kasparov vs junior drawn: turing test"</a>
<ul>
<li><strong>Previous message:</strong> <a href="2429.html">Lee Corbin: "RE: Fuel Efficient Cars (was Oil Economics)"</a>
<li><strong>In reply to:</strong> <a href="2399.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2666.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2666.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2430">[ date ]</a>
<a href="index.html#2430">[ thread ]</a>
<a href="subject.html#2430">[ subject ]</a>
<a href="author.html#2430">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<hr>
<!-- body="start" -->
<p>
Here is yet more evidence that selegiline (deprenyl) may increase
<br>
life-expectancy in humans. 
<br>
<p>In this study, treated animals enjoyed a 34% increase in life span.
<br>
<p>ABSTRACT:
<br>
Deprenyl increases the life span as well as activities of superoxide
<br>
dismutase and catalase but not of glutathione peroxidase in selective
<br>
brain regions in Fischer rats
<br>
<p>Kitani K, Kanai S, Carrillo MC, Ivy GO
<br>
<p>Radioisotope Research Institute,
<br>
Faculty of Medicine,
<br>
University of Tokyo, Japan.
<br>
Ann N Y Acad Sci 1994 Jun 30; 717:60-71
<br>
<p>ABSTRACT 
<br>
<p>(-)Deprenyl, a MAO-B inhibitor that is also known to be effective for
<br>
symptoms of Parkinson's disease, when injected subcutaneously (sc) in
<br>
male Fischer-344 rats at a dose of 0.5 mg/kg per day (3 times a week)
<br>
from 18 months of age, significantly increased the remaining life
<br>
expectancy. The average life span after 24 months was 34% greater in
<br>
treated rats than in saline-treated control animals. Furthermore, a
<br>
short-term (3 wk) continuous sc infusion of deprenyl significantly
<br>
increased activities of superoxide dismutase and catalase but not of
<br>
glutathione peroxidase in selective brain regions such as s. nigra,
<br>
striatum, and cerebral cortex, but not in hippocampus or cerebellum, or
<br>
the liver. The optimal dose for increasing these activities, however,
<br>
differed greatly depending on the sex and age of animals, with a 10-fold
<br>
lower value for young female than male rats.  Interestingly, aging
<br>
caused an increase and a decrease in the optimal dose in female and male
<br>
rats, respectively.  In addition, treatment for a longer term tended to
<br>
reduce the optimal dosage in the same animal group. The results clearly
<br>
demonstrate that deprenyl increases antioxidant enzyme activities in
<br>
selective brain regions.  If this effect of deprenyl is causally related
<br>
to its life-prolonging effect, the dosage to be used for any life span
<br>
study would be a critical factor, with the dosage differing widely
<br>
depending on sex, age of animal, and mode and duration of drug
<br>
administration. 
<br>
<!-- body="end" -->
<hr>
<ul>
<!-- next="start" -->
<li><strong>Next message:</strong> <a href="2431.html">gts: "RE: kasparov vs junior drawn: turing test"</a>
<li><strong>Previous message:</strong> <a href="2429.html">Lee Corbin: "RE: Fuel Efficient Cars (was Oil Economics)"</a>
<li><strong>In reply to:</strong> <a href="2399.html">gts: "RE: Performance enhancement with selegiline"</a>
<!-- nextthread="start" -->
<li><strong>Next in thread:</strong> <a href="2666.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<li><strong>Reply:</strong> <a href="2666.html">Rafal Smigrodzki: "RE: Performance enhancement with selegiline"</a>
<!-- reply="end" -->
<li><strong>Messages sorted by:</strong> 
<a href="date.html#2430">[ date ]</a>
<a href="index.html#2430">[ thread ]</a>
<a href="subject.html#2430">[ subject ]</a>
<a href="author.html#2430">[ author ]</a>
<a href="attachment.html">[ attachment ]</a>
</ul>
<!-- trailer="footer" -->
<hr>
<p><small><em>
This archive was generated by <a href="http://www.hypermail.org/">hypermail 2.1.5</a> 
: Mon Feb 10 2003 - 01:30:42 MST
</em></small></p>
</body>
</html>
